Medication info
Sitagliptin 100 mg Tablets (Sitagliptin Hydrochloride Monohydrate)

Sitagliptin 100 mg Tablets (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tablet
Manufacturer / importer
TDS Pharm Co., Ltd.
Appearance
Bright yellow-orange round film-coated tablets
Packaging
100 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202103505 · Approved 2021.04.29 · Insurance code 679802040

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
When used as monotherapy or in combination therapy, administer 100 mg once daily. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
TDS Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is used as an adjunct to dietary and exercise therapy and can also be used alone. In cases where prior diabetes medication treatment has not been experienced and monotherapy is insufficient, it can be combined with Metformin. Additionally, when blood sugar control is difficult with sulfonylurea, Metformin, thiazolidinedione, or insulin monotherapy, this medication is used as a combination treatment. It is also added as an adjunct in multiple drug combination therapies when sufficient blood sugar control is not achieved. Therefore, this medication plays an important role in improving blood sugar control in various situations.

How to take

Adult dose

When used as monotherapy or in combination therapy, administer 100 mg once daily. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). Patients with renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause allergic reactions; if symptoms such as rash, hives, or difficulty breathing occur, discontinue use immediately and consult a doctor. While taking this medication, serious pancreatitis can occur; therefore, if experiencing abdominal pain, vomiting, or persistent abdominal discomfort, inform healthcare professionals immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication, and those with allergies to this medication or its ingredients should also avoid it. Patients with impaired kidney function need to adjust the dosage of this medication, so it is important to discuss with a doctor to determine the appropriate dosage if there are kidney diseases. During treatment with this medication, signs of hypoglycemia may occur, especially when used in conjunction with insulin or sulfonylureas, so caution is advised. If severe joint pain or skin rash occurs, immediately discontinue use and seek medical attention from a specialist. Women who are pregnant or breastfeeding are not recommended to use this medication, and its safety in children under 18 years has not been established. Elderly patients are at higher risk of kidney function decline, thus regular kidney function tests before and after administration are important. In case of overdose, seek appropriate medical treatment immediately, and this remedy can be partially removed through hemodialysis. This medication may interact with other antihyperglycemic agents; therefore, inform your doctor or pharmacist of any other medications you are taking.

Side effects

Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, exfoliative dermatitis, acute pancreatitis, hypoglycemia, upper respiratory tract infections, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, joint pain associated with severe and disabling conditions, blistering similar to pemphigus, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased triglycerides in the blood, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air. It is recommended to store it at room temperature between 1 and 30 degrees Celsius. Proper storage can prolong the effectiveness of the medication.

Appearance and packaging

Appearance

Bright yellow-orange round film-coated tablets

Package unit

100 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.